Related Experiment Video

Updated: Dec 25, 2025

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.4K

Targeting the cyclin-dependent kinase 5 in metastatic melanoma

Samanta Sharma1,2, Tian Zhang3, Wojciech Michowski1,2

  • 1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215.

Proceedings of the National Academy of Sciences of the United States of America
|March 21, 2020
PubMed

Insights

Cyclin-dependent kinase 5 (CDK5) is crucial for cancer metastasis, not primary tumor growth. Inhibiting CDK5 effectively blocks the spread of melanoma cells, offering a potential therapeutic strategy against cancer dissemination.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Cyclin-dependent kinase 5 (CDK5) is known to be activated in various human cancers.
  • Its role in cancer progression, particularly in metastasis, requires further elucidation.

Purpose of the Study:

  • To investigate the role of CDK5 in melanoma growth and metastasis.
  • To explore the potential of CDK5 inhibition as a therapeutic strategy for metastatic melanoma.

Main Methods:

  • Utilized conditional CDK5 knockout mice and a highly metastatic melanoma mouse model.
  • Examined the effect of CDK5 ablation on primary tumor growth and metastatic spread.
  • Investigated the molecular mechanism by which CDK5 promotes invasiveness, focusing on vimentin phosphorylation.
  • Assessed the efficacy of chemical CDK5 inhibition in patient-derived xenograft (PDX) models.

Main Results:

  • CDK5 is dispensable for primary tumor growth but essential for metastatic spread in melanoma.
  • CDK5 directly phosphorylates vimentin, inhibiting its filament assembly and promoting cell invasiveness.
  • Chemical inhibition of CDK5 significantly blocked melanoma metastasis in PDX models.

Conclusions:

  • CDK5 plays a critical role in promoting melanoma cell invasiveness and metastasis.
  • Targeting CDK5 represents a promising therapeutic approach to prevent cancer dissemination.
Keywords:
CDK5cyclin-dependent kinasesmetastasismouse cancer models

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.7K
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.3K

Related Concept Videos

M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.3K